Summit Therapeutics (SMMT) News Today → War Over Taiwan? Protect Your Wealth NOW (From Behind the Markets) (Ad) Free SMMT Stock Alerts $3.75 +0.20 (+5.63%) (As of 11:54 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSummit Therapeutics (SMMT) Scheduled to Post Quarterly Earnings on Wednesdaymarketbeat.com - April 25 at 11:45 AMSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024businesswire.com - April 24 at 4:30 PMSummit Therapeutics (NASDAQ:SMMT) Shares Up 10.6%marketbeat.com - April 23 at 3:43 PMSummit Therapeutics (NASDAQ:SMMT) Stock Crosses Below Fifty Day Moving Average of $4.14americanbankingnews.com - April 23 at 5:34 AMShort Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Grows By 28.6%marketbeat.com - April 13 at 7:47 PMSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.7%marketbeat.com - April 12 at 3:59 PMSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directorsfinance.yahoo.com - April 11 at 5:11 PMSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directorsbusinesswire.com - April 11 at 4:30 PMSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forumbusinesswire.com - April 10 at 7:00 AMIllumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successorreuters.com - April 9 at 4:33 PMIllumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officerprnewswire.com - April 9 at 4:05 PMSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $3.95marketbeat.com - April 4 at 2:02 PMSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6%marketbeat.com - April 1 at 4:50 PMSummit Therapeutics CEO acquires shares worth over $411kinvesting.com - March 29 at 8:13 PMWhy Summit Therapeutics Stock Crushed the Market This Weekfool.com - March 29 at 5:43 PMInsider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Acquires 30,000 Shares of Stockinsidertrades.com - March 29 at 7:14 AMSummit Therapeutics (NASDAQ:SMMT) Trading 18.9% Higher After Insider Buying Activitymarketbeat.com - March 28 at 10:31 AMInsider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Buys 30,000 Shares of Stockmarketbeat.com - March 27 at 9:29 PMSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $3.28marketbeat.com - March 26 at 12:25 PMSummit Therapeutics (NASDAQ:SMMT) Trading 5% Higher marketbeat.com - March 20 at 2:21 PMSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.6%marketbeat.com - March 19 at 12:47 PMSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $4.62marketbeat.com - March 18 at 11:24 AMSummit Therapeutics Inc. (NASDAQ:SMMT) Short Interest Up 25.1% in Februarymarketbeat.com - March 14 at 11:38 PMIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024businesswire.com - March 14 at 7:00 AMSummit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.1%marketbeat.com - March 13 at 1:51 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMTprnewswire.com - March 11 at 6:05 PMSummit Therapeutics (NASDAQ:SMMT) Shares Up 6.7%marketbeat.com - March 5 at 3:17 PMSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conferencebusinesswire.com - March 5 at 7:00 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMTprnewswire.com - March 3 at 10:15 AMSHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) Investorsmsn.com - February 27 at 9:26 AMSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $4.64marketbeat.com - February 26 at 11:28 AMSummit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoingsbusinesswire.com - February 26 at 4:00 AMSummit Therapeutics plc (SMMT)uk.finance.yahoo.com - February 21 at 9:21 AMQ4 2023 Summit Therapeutics Inc Earnings Callfinance.yahoo.com - February 21 at 9:21 AMSummit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 21 at 9:21 AMSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $5.07marketbeat.com - February 20 at 11:34 AMSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023finance.yahoo.com - February 20 at 10:02 AMSummit Therapeutics Inc (SMMT) Reports Comprehensive 2023 Financial Results and Clinical ...finance.yahoo.com - February 20 at 10:02 AMSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023businesswire.com - February 20 at 7:00 AMSMMT Apr 2024 3.000 callfinance.yahoo.com - February 17 at 12:13 AMSMMT Mar 2024 4.000 putfinance.yahoo.com - February 17 at 12:13 AMSummit Therapeutics (NASDAQ:SMMT) Reaches New 52-Week High at $4.87marketbeat.com - February 16 at 10:53 AMSummit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024businesswire.com - February 14 at 10:29 AMSummit Therapeutics to Host Fourth Quarter & Full Year 2023finance.yahoo.com - February 14 at 10:18 AMSummit Therapeutics to Host Fourth Quarter & Full Year 2023businesswire.com - February 14 at 7:00 AMSummit Therapeutics (NASDAQ:SMMT) Shares Up 6.1%marketbeat.com - January 31 at 12:44 PMSummit Therapeutics: A Strategic Analysis Of Ivonescimab's Progressseekingalpha.com - January 30 at 8:39 AMSummit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 8 at 10:26 AMSummit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 9:43 AMSummit Therapeutics (NASDAQ:SMMT) Shares Up 15% on Insider Buying Activitymarketbeat.com - December 14 at 12:30 PM Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address War Over Taiwan? Protect Your Wealth NOW (Ad)With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared. Access my report now >>> SMMT Media Mentions By Week SMMT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SMMT News Sentiment▼0.300.33▲Average Medical News Sentiment SMMT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SMMT Articles This Week▼41▲SMMT Articles Average Week Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Evotec News Today Corcept Therapeutics News Today Merus News Today Janux Therapeutics News Today Vera Therapeutics News Today Rhythm Pharmaceuticals News Today Indivior News Today Arvinas News Today MorphoSys News Today Rocket Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SMMT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
